Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyHamish McAuley, A Alamoudi, James D. Chalmers et al.|EClinicalMedicine|2023Cited by 24
A randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye Khoo, Gareth Griffiths, Richard J. Fitzgerald et al.|medRxiv|2025Cited by 1